Skip to main content
. 2022 Apr 22;2022:3691635. doi: 10.1155/2022/3691635

Figure 6.

Figure 6

Knockdown of BCKDK reduces tumorigenic properties of HO8910-PM cells in vivo. (a) Mice and (b) tumors dissected from each group are shown. (c) Final average tumor growth curve and (d) tumor weight of mice injected with HO8910-PM-shMock or HO8910-PM-shBCKDK cells are shown. Data are shown as means ± standard deviation of measurements. The asterisk indicates a significant decrease in tumor size of HO8910-PM-shBCKDK-injected mice compared with HO8910-PM-shMock-injected mice (∗P < 0.05). (e) Immunohistochemistry analysis was performed in the tumor tissues of HO8910-PM-shMock-injected mice or HO8910-PM-shBCKDK-injected mice.